Form 8-K PALVELLA THERAPEUTICS, For: Sep 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Palvella Therapeutics (PVLA) PT Raised to $90 at Oppenheimer
September 24, 2025 1:17 PM EDTOppenheimer analyst Trevor Allred raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $90.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Palvella hosted a webcast this morning demonstrating the unmet need and high market potential for Qtorin rapamycin in clinically significant angiokeratomas.... More
